Waldenström's macroglobulinemia

Reviews in Clinical and Experimental Hematology

Volumn 6, Issue 4, 2002, Pages 421-434

  Johnson, Stephen A ^a  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE; CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GAMMA INTERFERON; IMMUNOGLOBULIN D; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; PACLITAXEL; PARAPROTEIN; PREDNISOLONE; PURINE DERIVATIVE; RITUXIMAB; THALIDOMIDE;

AUTOIMMUNE DISEASE; AUTOTRANSPLANTATION; B LYMPHOCYTE; BLOOD TOXICITY; BLOOD VISCOSITY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOPENIA; HUMAN; LUNG DISEASE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHENOTYPE; PLASMAPHERESIS; REVIEW; SKIN DISEASE; SOMATIC HYPERMUTATION; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0038441571     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2002.00307.x     Document Type: Review

References (83)

1. Waldenström J. Incipient myelomatosis or "essential" hyperglobulinemia with fibrinogenopenia - a new syndrome? Acta Med Scand, 117: 216-217, 1944.
2. Bjorkholm M, Celsing F, Runarsson G, Waldenström J. Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenström's macroglobulinemia. Int J Hematol, 62: 117-120, 1995.
3. Dimopoulous MA, Panayiotidis P, Moulopoulos LA, et al. Waldenström's macroglobulinemia, clinical features, complications and management. J Clin Oncol, 18: 214-226, 2000.
4. Berger F, Isaacson PG, Piris MA, et al. Lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia. In: Pathology and Genetics. Tumors of haematopoietic and lymphoid tissues. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). WHO OMS. IARC Press, Lyon; pp. 132-134, 2001.
5. Owen RG, Johnson SA, Morgan GJ. Waldenström's macroglobulinaemia. laboratory diagnosis and treatment. Haematol Oncol, 18: 41-49, 2000.
6. Owen RG, Barrans SL, Richards SJ, et al. Waldenströms macroglobulinaemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol, 116: 420-428, 2001.
7. Matutes E, Owusu-Ankormah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia, 8: 1640-1645, 1994.
8. Papamichael D, Norton AJ, Foran JM, et al. Immunocytoma: a retrospective analysis from St. Bartholomew's Hospital - 1972-96. J Clin Oncol, 17: 2847-2853, 1999.
9. Owen RG, Parapia LA, Higginson J, et al. Clinicopathological correlates of IgM paraproteinemias. Clin Lymphoma, 1: 39-43, 2000.
10. Kyle RA and Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc, 62: 719-731, 1987.
11. Valdez R, Finn WG, Ross CW, et al. Waldenström macroglobulinaemia caused by extranodal marginal zone B-cell lymphoma. Am J Clin Pathol, 116: 683-690, 2001.
12. Isaacson PG, Berger F, Piris MA, et al. Splenic marginal zone lymphoma. In: Pathology and Genetics. Tumors of haematopoietic and lymphoid tissues. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). WHO OMS. IARC Press, Lyon; pp. 135-137, 2001.
13. Nordquist LF, Saba HI, Moscinski LC. IgM myeloma: an IgM gammopathy distinct from Waldenström's macroglobulinemia. Hematology, 6: 53-58, 2001.
14. Dierlamm T, Laack E, Dierlamm J, et al. IgM myeloma. a report of four cases. Ann Hematol, 81: 136-139, 2002.
15. Wagner SD, Martinelli V, Luzzatto L. Similar patterns of VK gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Walclenström's macroglobulinemia and myeloma. Blood, 83: 3647-3653, 1994.
16. Aoki H, Takishita M, Kosaka M, et al. Frequent somatic mutation in D and/or JH segments of Ig gene in Waldenström's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood, 85: 1913-1919, 1995.
17. Ivanovski M, Silvestri F, Pozzato G, et al. Somatic hypermutation, clonal diversity, preferential expression of the VH 51pl/VL KV 325 immunoglobulin gene combination in hepatitis C virus-associatecl immunocytomas. Blood, 91: 2433-2442, 1998.
18. Stevenson F, Sahota S, Zhu D, et al. Insight into the origin and clonal history of Bcell tumours as revealed by analysis of immunoglobulin variable region genes. Immunol Rev, 162: 247-259, 1998.
19. Sahota SS, Forconi F, Ottensmeier CH, et al. Typical Waldenström's macroglobulinaemia and IgM-secreting MGUS are each derived from B-cells arrested following cessation of somatic mutation but prior to isotype switch events. Blood, 98: 154a, 2001.
20. Schop RFJ, Tschumper RE, Jelinek DF, et al. Heavy chain somatic hypermutation status in Waldenström's macroglobulinaemia. Blood, 98: 154a, 2001.
21. Manssor A, Medeiros LJ, Weber DM, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström Macroglobulinaemia. Am J Clin Pathol, 116: 543-549, 2001.
22. Wong KF and So CC. Waldenström macroglobulinemia with karyotypic aberrations involving both homologous 6q. Cancer Genet Cytogenet, 124: 137-139, 2001.
23. Mansoor A, Medeiros LJ, Weber DM, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol, 116: 543-549, 2001.
24. Schop RF, Jalal SM, Van Wier SA, et al. Deletions of 17p, 13.1 and 13q14 are uncommon in Waldenström's macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet, 132: 55-60, 2002.
25. Offit K, Parsa NZ, Filippa D, et al. t(9;14) (p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood, 80: 2594-2599, 1992.
26. Iida S, Rao PH, Nallasivam P, et al. The t(9;14) (p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood, 88: 4110-4117, 1996.
27. Groves FD, Travis LB, Devesa SS, et al. Waldenström's macroglobulinemia, incidence patterns in the United States 1988-94. Cancer, 82: 1078-1081, 1998.
28. Gertz MA and Kyle RA. Hyperviscosity syndrome. J Intens Care Med, 10: 128-141, 1995.
29. Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C viral infection and mixed cryogloblinemia. Blood, 84: 3047-3053, 1996.
30. Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia. J Clin Oncol, 11: 914-920, 1993.
31. Gardyn J, Schwartz A, Gal R, et al. Waldenström's macroglobulinemia associated with AA amyloidosis. Int J Hematol, 74: 76-78, 2001.
32. Vital A, Favereaux A, Martin-Dupont P, et al. Anti-myelin-associated glycoprotein antibodies and endoneural cryoglobulin deposits responsible for severe neuropathy. Acta Neuropathol, 102: 409-412, 2001.
33. Noerager BD, Inuzuka T, Kira J, et al. An IgM anti-MBP Ab in a case of Waldenström's macroglobulinemia with polyneuropathy expressing an idiotype reactive with an MBP epitope immunodominant in MS and EAE. J Neuroimmunol, 113: 163-169, 2001.
34. Harada Y, Ido N, Okada T, et al. Nephrotic syndrome caused by protein thrombi in glomerulocapillary lumen in Waldenström's macroglobulinaemia. Br J Haematol, 110: 874-875, 2000.
35. Libow LF, Mawhinney JP, Bessinger CT. Cutaneous Waldenström's macroglobulinemia: report of a case and overview of the spectrum of cutaneous disease. J Am Acad Dermatol, 45: 5202-5206, 2001.
36. Kyrtsonis MC, Angelopoulu MK, Kontopidou FN, et al. Primary lung involvement in Waldenström's macroglobulinemia, report of two cases and review of the literature. Acta Haematol, 105: 92-96, 2001.
37. Gobbi PG, Bettini R, Montecucco C, et al. Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood, 83: 2939-2945, 1994.
38. Facon T, Brouillard M, Duhamer A, et al. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. J Clin Oncol, 11: 1553-1558, 1993.
39. Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood, 96: 852-858, 2000.
40. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, et al. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patient. Experience from a single hematology unit. Ann Hematol, 80: 722-727, 2001.
41. Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol, 115: 575-582, 2001.
42. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (South West Oncology Group S9003). Blood, 98: 41-48, 2001.
43. Drew MJ. Plasmapheresis in the dysproteinemias. Ther Apher; 6: 45-52, 2002.
44. Reinhart WH, Lutolf O, Nydegger U, et al. Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: influence on blood rheology and the microcirculation. J Lab Clin Med, 119: 69-76, 1992.
45. Buskard NA, Galton DAG, Goldman JM, et al. Plasma exchange in the long-term management of Waldenström's macroglobulinemia. CMA J, 117: 135-137, 1997.
46. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Int Med, 131: 453-462, 1999.
47. Kyle RA, Greipp PR, Gertz MA, et al. Waldenström's macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol, 2000: 737-742, 2000.
48. Dimopoulos MA and Alexanian R. Waldenström's macroglobulinaemia. Blood, 83: 1452-1459, 1994.
49. Case DC, Ervin TJ, Boyd MA, et al. Waldenström's macroglobulinemia: long term results with the M-2 protocol. Cancer Invest, 9: 1-7, 1991.
50. Petrucci MT, Avvisati G, Tribalto M, et al. Waldenström's macroglobulinemia: results of a combined oral treatment in 34 newly diagnosed patients. J Intern Med, 226: 443-447, 1989.
51. Kantarjian HM, Alexanian R, Koller CA, et al. Fludarabine therapy in macroglobulinemic lymphoma. Blood, 75: 1928-1931, 1990.
52. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenström's macroglobulinemia. Am J Med, 95: 49-52, 1993.
53. Zinzani PL, Gherlinzoni F, Bendandi M, et al. Fludarabine treatment in resistant Waldenström's macroglobulinemia. Eur J Haematol, 54: 120-123, 1995.
54. LeBlond V, Ben-Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. J Clin Oncol, 16: 2060-2064, 1998.
55. LeBlond V, Levy V, Maloisel F, et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood, 98: 2640-2644, 2001.
56. Foran JM, Rohatiner AZS, Coiffier B, et al. Multicentre phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinaemia and Mantle Cell Lymphoma. J Clin Oncol, 17: 546-553, 1999.
57. Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med, 118: 195-198, 1993.
58. Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenström's macroglobulinemia with 2 chlorodeoxyadenosine. J Clin Oncol, 12: 2694-2698, 1994.
59. Dimopoulos MA, Weber DM, Delasalle KB, et al. Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol, 6: 49-52, 1995.
60. Delannoy A, Van den Neste E, Michaux JL, et al. Cladribine for Waldenström's macroglobulinemia. Br J Haematol, 104: 928-936, 1999.
61. Betticher DC, Hsu Schmitz SF, Ratschiller D, et al. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pre-treated Waldenström's macroglobulinaemia. Br J Haematol, 99: 358-363, 1997.
62. Liu ES, Burian C, Miller HE, et al. Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Br J Haematol, 103: 690-695, 1998.
63. Lewandowski K, Zaucha JM, Bieniaszewsa M, et al. 2-Chlorocteoxyadenosine treatment of Waldenström's macroglobulinemia - the analysis of own experience and the review of literature. Med Sci Monit, 6: 740-745, 2000.
64. Maloisel F, Campos F, Giron C, et al. Second treatment with fludarabine in a Waldenström's macroglobulinemia patient. Leukemia, 14: 220, 2000.
65. Lewandowski K, Halaburda K, Hellman A. Fludarabine therapy in Waldenström's macroglobulinaemia patients treated previously with 2-chlorodeoxyadenosine. Leuk Lymphoma, 43: 361-363, 2002.
66. Levy V, Porcher R, Leblond V, et al. French Co-operative Group on CLL and Macroglobulinemia. Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis. Leukemia, 15: 1466-1470, 2001.
67. Rotoli B, DeRenzo A, Frigeri F, et al. A phase II trial on alpha-interferon (αIFN) effect in patients with monoclonal IgM gammopathy. Leuk Lymphoma, 13: 463-469, 1994.
68. Quesada JR, Alexanian R, Kurzrock R, et al. Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenström's macroglobulinemia. Am J Hematol, 29: 1-4, 1988.
69. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenström's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol, 10: 1525-1527, 1999.
70. Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantlecell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol, 18: 317-324, 2000.
71. Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macroglobulinemia. J Immunother, 24: 272-279, 2001.
72. Dimopoulous MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with Rituximab. J Clin Oncol, 20: 2327-2333, 2002.
73. Weide R, Haymanns J, Koppler H. The polyneuropathy associated with Waldenström's macroglobulinemia can be treated effectively with chemotherapy and the antiCD20 monoclonal antibody rituximab. Br J Haematol, 109: 838-841, 2001.
74. Dimopoulos MA, Zomas A, Vinion NA, et al. Treatment of Waldenström's macroglobulinaemia with thalidomide. J Clin Oncol, 19: 3596-3601, 2001.
75. Jane SM and Salem HH. Treatment of resistant Waldenström's macroglobulinemia with high dose glucocorticosteroids. Aust NZ J Med, 18: 77-78, 1988.
76. Clamon GH, Corder MP, Burns CP. Successful doxorubicin therapy of primary macroglobulinemia resistant to alkylating agents. Am J Hematol, 9: 221-223, 1980.
77. Dimopoulos MA, Luckett R, Alexanian R. Primary therapy of Waldenström's macroglobulinemia with paclitaxel. J Clin Oncol, 12: 2694-2698, 1994.
78. Yang L, Wen BP, Li HM, et al. Autologous peripheral stem cell transplantation for Waldenström's macroglobulinaemia. Bone Marrow Transplant, 24: 929-930, 1999.
79. Desikan R, Dhodapkar M, Siegel D, et al. High dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia. Br J Haematol, 105: 993-996, 1999.
80. Dreger P, Glass B, Kuse R, et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia. Br J Haematol, 106: 115-118, 1999.
81. Anagnostopoulos A, Dimopoulos MA, Aleman A, et al. High-dose chemotherapy followed by stem cell transplantation in patient with resistant Waldenström's macroglobulinemia. Bone Marrow Transplant, 27: 1027-1029, 2001.
82. Martino R, Shah A, Romero P, et al. Allogeneic bone marrow transplantation for advanced Waldenström's macroglobulinemia. Bone Marrow Transplant, 23: 747-749, 1999.
83. Ueda T, Hatanaka K, Kosugi S, et al. Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinaemia with severe pancytopenia. Bone Marrow Transplant, 28: 609-611, 2001.